Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vimian Group AB ( (SE:VIMIAN) ) just unveiled an announcement.
Vimian Group AB has agreed to acquire I-Vet, a leading Italian provider of reference laboratory services and in-clinic diagnostic solutions for companion animals, which serves some 5,000 veterinary clinics and generates annual revenues of around EUR 5.6 million. The deal, Vimian’s fifth acquisition in 2025, will fold I-Vet into its Diagnostics segment, retain CEO and founder Daniele Franzini at the helm, and is financed with existing cash, underscoring Vimian’s strategy to deepen its footprint in the fast-growing companion animal diagnostics market while having only a marginal impact on earnings per share in 2026.
The most recent analyst rating on (SE:VIMIAN) stock is a Hold with a SEK39.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.
More about Vimian Group AB
Vimian Group AB is a global animal health company operating across Specialty Pharma, MedTech, Veterinary Services and Diagnostics, focused on providing innovative products and services to veterinary professionals and pet owners. Headquartered in Stockholm, the group reaches more than 17,000 veterinary clinics and laboratories in over 80 markets, employs around 1,200 people and generates annual revenues of about EUR 375 million.
Average Trading Volume: 304,576
Technical Sentiment Signal: Sell
Current Market Cap: SEK15.72B
See more insights into VIMIAN stock on TipRanks’ Stock Analysis page.